Prescribing of Electronic Activity Monitors in Cardiometabolic Diseases: Qualitative Interview-Based Study

por Bellicha, Alice, Macé, Sandrine, Oppert, Jean-Michel
Publicado 2017

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma

por Richardson, Paul G., Facon, Thierry, Bensinger, William I., Leleu, Xavier, Campana, Frank, Macé, Sandrine, Chiron, Marielle, van de Velde, Helgi, Mikhael, Joseph
Publicado 2021

Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma

por Sun, Haibo, Martin, Thomas G, Marra, John, Kong, Denice, Keats, Jonathon, Macé, Sandrine, Chiron, Marielle, Wolf, Jeffrey L, Venstrom, Jeffrey M, Rajalingam, Raja
Publicado 2021

P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY

por Facon, Thierry, Moreau, Philippe, Špicka, Ivan, Suzuki, Kenshi, Yong, Kwee, Mikhael, Joseph, Fukao, Taro, Bisht, Kamlesh, Armstrong, Nicole, Macé, Sandrine, Risse, Marie-Laure, Martin, Thomas
Publicado 2023

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

por Martin, Tom, Richardson, Paul G., Facon, Thierry, Moreau, Philippe, Perrot, Aurore, Spicka, Ivan, Bisht, Kamlesh, Inchauspé, Marlene, Casca, France, Macé, Sandrine, van de Velde, Helgi, Suzuki, Kenshi
Publicado 2022

Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

por Ocio, Enrique M., Bringhen, Sara, Martinez-Lopez, Joaquin, San-Miguel, Jesus, Oliva, Stefania, Rodriguez-Otero, Paula, Le Roux, Nadia, Dong, Yvonne, Doroumian, Severine, Macé, Sandrine, Mateos, Maria-Victoria
Publicado 2023

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS

por Moreau, Philippe, Perrot, Aurore, Dimopoulos, Meletios A., Martin, Thomas, Facon, Thierry, Eduardo Capra, Marcelo, Beksac, Meral, Armstrong, Nicole, Dubin, Franck, Macé, Sandrine, Risse, Marie-Laure, Tekle, Christina, Klippel, Zandra, Richardson, Paul
Publicado 2023

Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma

por Hulin, Cyrille, Beksac, Meral, Goodman, Hugh J., Spicka, Ivan, Alegre, Adrian, Prince, Miles, Campana, Frank, Finn, Greg, Le-Guennec, Solenn, Macé, Sandrine, Muccio, Stéphane, Tavernier, Alexandra, Rouchon, Marie-Claude, Richardson, Paul G.
Publicado 2021

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study

por Boissel, Nicolas, Chevallier, Patrice, Doronin, Vadim, Griskevicius, Laimonas, Maschan, Alexey, McCloskey, James, Rambaldi, Alessandro, Rossi, Giuseppe, Sokolov, Andrey, Wartiovaara‐Kautto, Ulla, Oprea, Corina, Abbadessa, Giovanni, Gosselin, Alice, Macé, Sandrine, Thomas, Xavier
Publicado 2022

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

por de Weger, Vincent A., de Jonge, Maja, Langenberg, Marlies H. G., Schellens, Jan H. M., Lolkema, Martijn, Varga, Andrea, Demers, Brigitte, Thomas, Koruth, Hsu, Karl, Tuffal, Gilles, Goodstal, Samantha, Macé, Sandrine, Deutsch, Eric
Publicado 2018

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

por Jung, Joonil, Lee, Joon Sang, Dickson, Mark A., Schwartz, Gary K., Le Cesne, Axel, Varga, Andrea, Bahleda, Rastilav, Wagner, Andrew J., Choy, Edwin, de Jonge, Maja J., Light, Madelyn, Rowley, Steve, Macé, Sandrine, Watters, James
Publicado 2016

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma

por Martin, Thomas, Mikhael, Joseph, Hajek, Roman, Kim, Kihyun, Suzuki, Kenshi, Hulin, Cyrille, Garg, Mamta, Quach, Hang, Sia, Hanlon, George, Anup, Konstantinova, Tatiana, Risse, Marie-Laure, Asset, Gaelle, Macé, Sandrine, van de Velde, Helgi, Moreau, Philippe
Publicado 2022

Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping

por Chami, Btissam, Okuda, Makoto, Moayeri, Morvarid, Pirenne, France, Hidaka, Yoko, Nambiar, Ashok, Song, Zhili, Bedel, Olivier, Zhang, Bailin, Hopke, Joern, Deng, Gejing, Zhu, Chen, Macé, Sandrine, Chiron, Marielle, Adrian, Francisco, Fukao, Taro, Basile, Frank G., Martin, Thomas
Publicado 2022

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis

por Spicka, Ivan, Moreau, Philippe, Martin, Thomas G., Facon, Thierry, Martinez, Gracia, Oriol, Albert, Koh, Youngil, Lim, Andrew, Mikala, Gabor, Rosiñol, Laura, Yağci, Münci, Cavo, Michele, Risse, Marie‐Laure, Asset, Gaëlle, Macé, Sandrine, van de Velde, Helgi, Yong, Kwee
Publicado 2022

P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES

por Perrot, Aurore, Richardson, Paul, Mikhael, Joseph, Martin, Thomas G., Beksac, Meral, Spicka, Ivan, Eduardo Capra, Marcelo, D’agostino, Mattia, Sonneveld, Pieter, Bisht, Kamlesh, Fukao, Taro, Zhang, Rick, Tada, Keisuke, Tekle, Christina, Macé, Sandrine, Klippel, Zandra, van de Velde, Helgi, Moreau, Philippe
Publicado 2023

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics

por Harrison, Simon J., Perrot, Aurore, Alegre, Adrian, Simpson, David, Wang, Ming Chung, Spencer, Andrew, Delimpasi, Sosana, Hulin, Cyrille, Sunami, Kazutaka, Facon, Thierry, Vlummens, Philip, Yong, Kwee, Campana, Frank, Inchauspé, Marlène, Macé, Sandrine, Risse, Marie‐Laure, van de Velde, Helgi, Richardson, Paul
Publicado 2021

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

por Mehra, Niven, Dolling, David, Sumanasuriya, Semini, Christova, Rossitza, Pope, Lorna, Carreira, Suzanne, Seed, George, Yuan, Wei, Goodall, Jane, Hall, Emma, Flohr, Penny, Boysen, Gunther, Bianchini, Diletta, Sartor, Oliver, Eisenberger, Mario A., Fizazi, Karim, Oudard, Stephane, Chadjaa, Mustapha, Macé, Sandrine, de Bono, Johann S.
Publicado 2018

Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study

por Sunami, Kazutaka, Suzuki, Kenshi, Ri, Masaki, Matsumoto, Morio, Shimazaki, Chihiro, Asaoku, Hideki, Shibayama, Hirohiko, Ishizawa, Kenichi, Takamatsu, Hiroyuki, Ikeda, Takashi, Maruyama, Dai, Kaneko, Hitomi, Uchiyama, Michihiro, Kiguchi, Toru, Iyama, Satoshi, Murakami, Hirokazu, Takahashi, Keishiro, Tada, Keisuke, Macé, Sandrine, Guillemin‐Paveau, Hélène, Iida, Shinsuke
Publicado 2020

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

por Martin, Thomas, Dimopoulos, Meletios-Athanasios, Mikhael, Joseph, Yong, Kwee, Capra, Marcelo, Facon, Thierry, Hajek, Roman, Špička, Ivan, Baker, Ross, Kim, Kihyun, Martinez, Gracia, Min, Chang-Ki, Pour, Ludek, Leleu, Xavier, Oriol, Albert, Koh, Youngil, Suzuki, Kenshi, Casca, France, Macé, Sandrine, Risse, Marie-Laure, Moreau, Philippe
Publicado 2023

P501: ISATUXIMAB PLUS CHEMOTHERAPY FOR PEDIATRIC RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA OR ACUTE MYELOID LEUKEMIA (ISAKIDS): INTERIM EFFICACY ANALYSIS

por Baruchel, André, Bertrand, Yves, Nysom, Karsten, Jin Kang, Hyoung, Makiya, Monica, Abrahamsson, Jonas, González-Llano, Oscar, Quinones Choque, Willy, Rizzari, Carmelo, Buechner, Jochen, Cesaro, Simone, Duarte, Ximo, Fagioli, Franca, Kattamis, Antonis, Leverger, Guy, Nelken, Brigitte, Wang, Lynn, Mace, Sandrine, Oprea, Corina, Abbadessa, Giovanni, Zwaan, Michel
Publicado 2023